Two New Drugs Offer Hope for Pancreatic Cancer

Pancreatic cancer is one of the most challenging diseases to treat; while survival rates have improved since the 1970s, they have plateaued in recent years. But two promising drugs in the pipeline each seem to double survival.

Revolution Medicines reported on April 13 that its cancer pill, daraxonrasib, helped patients survive an average of 13.2 months after starting treatment, compared to 6.7 months for those receiving standard chemotherapy. “These are dramatic results, with practice-changing outcomes,” said Dr. Mark Goldsmith, CEO of Revolution Medicines, in an interview with TIME.

The following day, research supported by another company, Actuate Therapeutics, was published in Nature Medicine showing that the company's pancreatic cancer drug, elraglusib, also doubled one-year survival for patients taking it compared to those getting standard chemotherapy. Elraglusib is given by IV.

Please select this link to read the complete article from TIME.